People with multiple sclerosis (PwMS) commonly use complementary and alternative
medicines (CAM), but an understanding of their efficacy is lacking. Here, we quantitatively …

Primary progressive multiple sclerosis (PPMS) shows a highly variable disease progression
with poor prognosis and a characteristic accumulation of disabilities in patients. These …

Background Several disease-modifying therapies (DMTs) treat relapsing–remitting multiple
sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Few comprehensive …

Background Several disease-modifying drug therapies are available for the treatment of
multiple sclerosis (MS). To ensure the most appropriate MS management, we assessed the …

Background Chronic visual loss is a disabling feature in patients with multiple sclerosis
(MS). It was recently shown that MD1003 (high-dose pharmaceutical-grade biotin or hdPB) …

Background: Several natural history studies on primary progressive multiple sclerosis
(PPMS) patients detected a consistent heterogeneity in the rate of disability accumulation …

Objective To determine if ovarian aging as measured by levels of anti-Müllerian hormone
(AMH) is associated with pattern of multiple sclerosis (MS) progression in women. Methods …

Objective To investigate the relationship between brain volume and disability worsening
over≥ 3 years in the natural history of primary progressive multiple sclerosis using data from …

Background: Primary progressive multiple sclerosis (PPMS) represents 10%–15% of all
multiple sclerosis (MS) diagnoses. Information regarding socio-demographic and clinical …

Multiple sclerosis (MS) is the most common immune-mediated inflammatory demyelinating
disease of the central nervous system. The onset and phenotypes of MS will be reviewed …